http://www.millerandzois.com/Fleet-Phospho-soda-lawyer.htmlOur lawyers are now looking at potential class action cases involving oral sodium phosphate products. The FDA indicated in December, through a MedWatch Safety Alert, that oral sodium phosphates (OSP) bowel cleansing solutions should be available by prescription only.
The MedWatch Safety Alert, with the cumbersome title, "Oral Sodium Phosphate (OSP) Products for Bowel Cleansing: reports of acute phosphate nephropathy, Boxed Warning to be added to labeling,” reported serious kidney injuries were associated with the use of oral sodium phosphate products (OSP) for bowel cleansing prior to not only colonoscopies but other less invasive procedures. The MedWatch also noted something that will be critical in proving these lawsuits: they have found kidney injuries with patients that not only did not have prior kidney injury but also did not have markers that would make them candidates for this particular kidney injury (acute phosphate nephropathy).
Acute phosphate nephropathy, often called acute nephrocalcinosis, is a very serious kidney injury that can require dialysis or a kidney transplant and can lead to acute renal failure and even death.
The FDA is also concerned with all potential kidney injuries and risks associated with the use of OSP products that are available over-the-counter (OTC). The reason the OTC problem is more severe is because the injury appears to be dose responsive.
Continue reading "
Lawyers for Oral Sodium Phosphate (OSP) Kidney Injury
" »